1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health; 2016.
2. Ganser A, Raymond S, Pearson J. Data quality and power in clinical trials: A comparison of ePRO and paper in a randomized trial. In: Byrom B, Tiplady B, editors. ePro: Electronic Solutions for Patient-Reported Data: Gower; 2010. p. 49.
3. FDA. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. [accessed 13 March 2023].
4. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force;Eremenco S;Value Health,2014
5. Miseta E. What Is driving the adoption of EDC applications?: Clinical Leader; 2021. https://www.clinicalleader.com/doc/what-is-driving-the-adoption-of-edc-applications-0001. [